AbCellera Biologics Inc.
ABCL
$2.37
-$0.025-1.05%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -24.17% | -34.59% | -77.23% | -80.23% | -92.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -24.17% | -34.59% | -77.23% | -80.23% | -92.17% |
| Cost of Revenue | -4.78% | 8.27% | 3.87% | 4.07% | 0.77% |
| Gross Profit | -0.58% | -28.56% | -770.43% | -604.45% | -144.24% |
| SG&A Expenses | 13.72% | 18.93% | 14.26% | 11.54% | 12.61% |
| Depreciation & Amortization | 141.24% | 285.24% | 151.88% | 13.15% | 25.46% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.21% | 35.91% | 19.47% | 6.94% | 5.65% |
| Operating Income | -19.21% | -53.62% | -149.56% | -250.05% | -205.47% |
| Income Before Tax | -15.15% | -28.90% | -151.93% | -323.06% | -172.79% |
| Income Tax Expenses | -35.85% | 4.79% | -970.72% | -310.88% | -134.29% |
| Earnings from Continuing Operations | -11.24% | -36.13% | -107.42% | -192.84% | -192.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.24% | -36.13% | -107.42% | -192.84% | -192.35% |
| EBIT | -19.21% | -53.62% | -149.56% | -250.05% | -205.47% |
| EBITDA | 10.83% | -24.66% | -148.92% | -363.00% | -187.09% |
| EPS Basic | -9.28% | -33.82% | -105.07% | -190.07% | -190.59% |
| Normalized Basic EPS | -9.75% | -54.89% | -215.91% | -538.13% | -171.25% |
| EPS Diluted | -7.56% | -34.93% | -96.72% | -176.20% | -205.69% |
| Normalized Diluted EPS | -9.75% | -54.89% | -193.48% | -449.93% | -179.11% |
| Average Basic Shares Outstanding | 1.79% | 1.71% | 1.62% | 1.53% | 1.44% |
| Average Diluted Shares Outstanding | 1.79% | 1.71% | -1.01% | -1.11% | -3.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
